BioTuesdays
Viking Therapeutics Logo
Markets

WB starts Viking Therapeutics at OP

William Blair launched coverage of Viking Therapeutics (NASDAQ:VKTX) with an “outperform” rating. The stock closed at $3.97 on April 27. Viking has a differentiated clinical pipeline focusing on modulating hormone...

April 30, 2018
Dova Pharmaceuticals
Markets

Ladenburg starts Dova Pharma at buy; PT $65

Ladenburg Thalmann initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “buy” rating and $65 price target. The stock was quoted at $26.55 near the close on April 26. Dova is focused on the development and...

April 26, 2018
Prothena
Markets

BTIG cuts Prothena to neutral; discontinues PT

BTIG downgraded Prothena (NASDAQ:PRTA) to “neutral” without a price target after the company discontinued development of NEOD001, an investigational antibody being evaluated to treat AL amyloidosis. The stock dropped...

April 24, 2018
Cipher Pharmaceuticals
Markets

Mackie cuts Cipher Pharma PT to $5.30 from $7.10

Mackie Research Capital lowered its price target for Cipher Pharmaceuticals (TSX:CPH) to $5.30 from $7.10 after the company lowered first quarter expectations on the back of weak Absorica sales. Analyst Andre Uddin...

April 24, 2018
Homology Logo
Markets

BTIG starts Homology Medicines at buy; PT $35

BTIG initiated coverage of Homology Medicines (NASDAQ:FIXX) with a “buy” rating and $35 price target. The stock closed at $19.90 on April 23. Founded in 2015, Homology is a genetic medicine company that is focused on...

April 24, 2018
Matinas Biopharma
Markets

Maxim cuts Matinas BioPharma PT to $4 from $6

Maxim Group lowered its price target for Matinas BioPharma (NYSE American:MTNB) to $4 from $6, citing dilution from the company’s next financing. The stock closed at 68 cents on April 20. Analyst Jason McCarthy writes...

April 23, 2018
Knight Therapeutics
Markets

RBC starts Knight Therapeutics at OP; PT $9.50

RBC Capital Markets launched coverage of Knight Therapeutics (TSX:GUD) with an “outperform” rating and price target of $9.50. The stock closed at $7.79 on April 20. Knight’s focus is on the licensing and...

April 23, 2018
Ovid Therapeutics
Markets

Ladenburg starts Ovid Therapeutics at buy; PT $27

Ladenburg Thalmann initiated coverage of Ovid Therapeutics (NASDAQ:OVID) with a “buy” rating and $27 price target. The stock closed at $10.14 on April 19. Ovid is developing two clinical-stage candidates: OV101, a GABA...

April 20, 2018
Sientra Logo
Markets

Leerink resumes coverage of Sientra at OP; PT $19

Leerink resumed coverage of Sientra (NASDAQ:SIEN) with an “outperform” rating and $19 price target. The stock closed at $11.98 on April 19. Leerink suspended coverage of Sientra in 2015 following a CE Mark suspension...

April 20, 2018
IntriCon Logo
Markets

Stifel starts IntriCon at buy; PT $35

Stifel initiated coverage of IntriCon (NASDAQ:IIN) with a “buy” rating and $35 price and also added IntriCon to the Stifel Select List. The stock closed at $19.60 on April 16. “In our opinion, IntriCon is one of the...

April 17, 2018
Viveve Medical Logo
Markets

Stifel starts Viveve Medical at buy; PT $6

Stifel launched coverage of Viveve Medical (NASDAQ:VIVE) with a “buy” rating and $6 price target. The stock closed at $3.36 on April 16. Viveve is focused on development and marketing the Viveve system and the Geneveve...

April 16, 2018
Cutera
Markets

Stifel starts Cutera at hold; PT $55

Stifel initiated coverage of Cutera (NASDAQ:CUTR) with a “hold” rating and price target of $55. The stock closed at $54.60 on April 16. Cutera develops and manufactures products used various aesthetic procedures...

April 16, 2018
NeoGenomics
Markets

BTIG ups NeoGenomics to buy; PT $11

BTIG upgraded NeoGenomics (NASDAQ:NEO) to “buy” from “neutral” with a price target of $11, saying that with a cleaner slate, it expects the shares to outperform. The stock closed at $8.49 on April 13. Analyst Dr. Sean...

April 16, 2018
Apollo Endosurgery
Markets

Piper starts Apollo Endosurgery at overweight; PT $8

Piper Jaffray launched coverage of Apollo Endosurgery (NASDAQ:LAPEN) with an “overweight” rating and $8 price target. The stock closed at $5.85 on April 12. Apollo is focused on bariatric and general surgery procedures...

April 13, 2018
Aptevo Therapeutics
Markets

Roth start Aptevo at buy; PT $12

Roth Capital Partners initiated coverage of Aptevo Therapeutics (NASDAQ:APVO) with a “buy” rating and price target of $12. The stock closed at $3.28 on April 11. “In our view, Aptevo remains under the Street’s...

April 12, 2018
vTv Therapeutics Logo
Markets

Stifel cuts vTv Therapeutics to hold; PT to $1 from $12

Stifel downgraded vTv Therapeutics (NASDAQ:VTVT) to “hold” from “buy” and slashed its price target to $1 from $12 after the company reported negative top line results from its Phase 3 STEADFAST study in mild Alzheimer’s...

April 10, 2018
Exact Sciences Logo
Markets

BTIG ups Exact Sciences to buy; PT $60

BTIG upgraded Exact Sciences (NASDAQ:EXAS) to “buy” from “neutral” with a price target of $60, citing an approximate 35% drop in the stock price since November, which it said offers an “attractive entry point.” The...

April 3, 2018
Allena Pharmaceuticals Logo
Markets

Roth starts Allena Pharma at buy; PT $61

Roth Capital Partners initiated coverage of Allena Pharmaceuticals (NASDAQ: ALNA) with a “buy” rating and a $61 price target. The stock closed at $11.02 on March 29. Allena is focused on the treatment of enteric...

April 2, 2018
Flex Pharma
Markets

Ladenburg ups Flex Pharma PT to $20 from $13

Ladenburg Thalmann raised its price target for Flex Pharma (NASDAQ:FLKS) to $20 from $13 after the company announced that its lead asset, FLX-787, reduced the frequency of cramps/spasms in a 57-patient, placebo...

March 29, 2018